Rehmannioside D
CAS No. : 81720-08-3
| Size | Price | Stock |
|---|---|---|
| 1mg | $50 | In-stock |
| 5mg | $110 | In-stock |
| 10mg | $160 | In-stock |
| 25mg | $290 | In-stock |
| 50mg | $430 | In-stock |
| 100mg | $640 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N0912 |
| M.Wt: | 686.61 |
| Formula: | C27H42O20 |
| Purity: | >98 % |
| Solubility: | H2O : 100 mg/mL (ultrasonic) |
Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis[1][2].
In Vitro:Rehmannioside D (5-10 μM; 24 h) alleviates H2O2-induced apoptosis of AML12 cells by upregulating Sirt7 expression[1].
In Vivo:Rehmannioside D (10-40 mg/kg; i.g.; daily; 3 weeks) attenuates CCl4-induced liver fibrosis in male C57BL/6J mice[1].
Rehmannioside D (10-40 mg/kg; p.o.; daily; 2 weeks) attenuates DMN-induced liver fibrosis in male Wistar rats by upregulating Sirt7 expression, inhibiting acetyl-p53-mediated hepatocyte apoptosis, reducing hepatic injury, inflammation, and collagen deposition[1].
Rehmannioside D (19-76 mg/kg; i.g.; daily; 2 weeks) has an ameliorative effect in a rat model of impaired ovarian reserve[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Rehmannioside D
- Cat. No.:
- HY-N0912
- Quantity:
Your information is safe with us.